Form 4: Akebia Therapeutics SVP, Chief Operating Officer Michel Dahan Reports Sale of Common Stock for Tax Obligations
SEC Form 4
Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, Inc., reports the sale of 8,661 shares of common stock to cover tax withholding obligations.
Summary
- On February 29, 2024, Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, Inc., sold 8,661 shares of common stock.
- The sale was executed at a price of $1.58 per share.
- The transaction was made automatically by the Issuer to cover tax withholding obligations related to the vesting and settlement of restricted stock units granted on February 28, 2022.
- Following the transaction, Dahan beneficially owns 706,932 shares of Akebia Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document reports a routine stock sale for tax purposes, which is neutral in sentiment.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It doesn't necessarily reflect a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2022/02/28 | Date of grant for restricted stock units. |
| 2024/02/29 | Date of stock sale. |
| 2024/03/01 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.